Humacyte receives Nasdaq bid price notice; has until January 27, 2027 to regain compliance
Humacyte received a Nasdaq notice that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days ended July 30, 2026. The company has 180 calendar days, until January 27, 2027, to regain compliance, which requires a closing bid of $1.00 or more for at least 10 consecutive business days. Nasdaq says the notice has no immediate effect on the stock's listing, but the company cannot assure it will regain compliance.
Key points
- Notice received July 31, 2026, for 30 consecutive business days ended July 30, 2026 below $1.00 bid price
- Compliance period runs until January 27, 2027 (180 calendar days)
- Regaining compliance requires closing bid of $1.00 or more for at least 10 consecutive business days
- Stock continues to trade on The Nasdaq Global Select Market under HUMA
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.